Quotient
Market Cap
US$612.2m
Last Updated
2021/01/15 23:32 UTC
Data Sources
Company Financials +
Executive Summary
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has Quotient's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: QTNT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: QTNT's weekly volatility (9%) has been stable over the past year.
Market Performance
7 Day Return
6.1%
QTNT
-1.5%
US Medical Equipment
-0.9%
US Market
1 Year Return
-29.1%
QTNT
20.0%
US Medical Equipment
19.6%
US Market
Return vs Industry: QTNT underperformed the US Medical Equipment industry which returned 20.5% over the past year.
Return vs Market: QTNT underperformed the US Market which returned 21% over the past year.
Shareholder returns
| QTNT | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.1% | -1.5% | -0.9% |
| 30 Day | -13.1% | 4.9% | 3.0% |
| 90 Day | 22.4% | 7.3% | 11.5% |
| 1 Year | -29.1%-29.1% | 21.0%20.0% | 22.3%19.6% |
| 3 Year | 61.6%61.6% | 71.5%67.2% | 45.3%35.7% |
| 5 Year | -56.4%-56.4% | 167.2%147.2% | 124.8%99.9% |
Long-Term Price Volatility Vs. Market
How volatile is Quotient's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is Quotient (NASDAQ:QTNT) A Risky Investment?1 month ago | Simply Wall St
Quotient (NASDAQ:QTNT) Shareholders Have Enjoyed A 58% Share Price Gain2 months ago | Simply Wall St
New Forecasts: Here's What Analysts Think The Future Holds For Quotient Limited (NASDAQ:QTNT)Valuation
Is Quotient undervalued compared to its fair value and its price relative to the market?
18.15x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate QTNT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate QTNT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: QTNT is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: QTNT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate QTNT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: QTNT is overvalued based on its PB Ratio (18.2x) compared to the US Medical Equipment industry average (5x).
Next Steps
Future Growth
How is Quotient forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
20.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QTNT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: QTNT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: QTNT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: QTNT's revenue (37.6% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: QTNT's revenue (37.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if QTNT's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Quotient performed over the past 5 years?
-16.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QTNT is currently unprofitable.
Growing Profit Margin: QTNT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: QTNT is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.
Accelerating Growth: Unable to compare QTNT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QTNT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).
Return on Equity
High ROE: QTNT has a negative Return on Equity (-274.74%), as it is currently unprofitable.
Next Steps
Financial Health
How is Quotient's financial position?
Financial Position Analysis
Short Term Liabilities: QTNT's short term assets ($195.9M) exceed its short term liabilities ($43.5M).
Long Term Liabilities: QTNT's short term assets ($195.9M) exceed its long term liabilities ($194.6M).
Debt to Equity History and Analysis
Debt Level: QTNT's debt to equity ratio (529.1%) is considered high.
Reducing Debt: QTNT's debt to equity ratio has increased from 441.4% to 529.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: QTNT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: QTNT has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 7.8% each year.
Next Steps
Dividend
What is Quotient current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate QTNT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate QTNT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QTNT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QTNT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of QTNT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Franz Walt (61 yo)
2.83yrs
Tenure
US$2,290,335
Compensation
Mr. Franz Walt has been Chief Executive Officer of Quotient Limited since May 2018 and served as its Interim Chief Executive Officer from March 21, 2018 to May 2018. He has been Director at Quotient Limite...
CEO Compensation Analysis
Compensation vs Market: Franz's total compensation ($USD2.29M) is about average for companies of similar size in the US market ($USD2.38M).
Compensation vs Earnings: Franz's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.83yrs | US$2.29m | 0.38% $ 2.3m | |
| Chief Financial Officer | 0.92yr | US$897.86k | 0.0099% $ 60.6k | |
| Chief Operating Officer | 1yr | US$1.14m | 0.029% $ 180.4k | |
| Chief Commercial Officer | 2yrs | US$969.91k | 0.14% $ 866.1k | |
| Head of Financial Accounting & Treasury | 1yr | no data | 0.0090% $ 54.9k |
1.0yrs
Average Tenure
50yo
Average Age
Experienced Management: QTNT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.83yrs | US$2.29m | 0.38% $ 2.3m | |
| Non-Employee Independent Director | 7.5yrs | US$176.00k | 0.061% $ 371.4k | |
| Independent Non-Employee Director | 8.92yrs | US$160.00k | 0.045% $ 277.0k | |
| Independent Chairman of the Board | 2.83yrs | US$465.44k | 0.26% $ 1.6m | |
| Independent Director | 9.92yrs | US$232.00k | 0.10% $ 637.6k | |
| Independent Director | 0.33yr | no data | 0.0041% $ 25.2k | |
| Independent Director | 0.33yr | no data | 0.0041% $ 25.2k | |
| Independent Director | 8.67yrs | US$220.00k | 0.10% $ 610.6k |
5.2yrs
Average Tenure
67yo
Average Age
Experienced Board: QTNT's board of directors are considered experienced (5.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.9%.
Top Shareholders
Company Information
Quotient Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Quotient Limited
- Ticker: QTNT
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$612.192m
- Shares outstanding: 101.02m
- Website: https://www.quotientbd.com
Number of Employees
Location
- Quotient Limited
- B1, Business Park Terre Bonne
- Route de Crassier 13
- Eysins
- Vaud
- 1262
- Switzerland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| QTNT | NasdaqGM (Nasdaq Global Market) | Yes | Ordinary Shares | US | USD | May 2014 |
| U4W | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | May 2014 |
Biography
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/15 23:32 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.